VBI Vaccines (VBIV) Trading Up 2.5%

VBI Vaccines Inc (NASDAQ:VBIV)’s share price was up 2.5% on Thursday . The stock traded as high as $2.03 and last traded at $2.02. Approximately 8,300 shares changed hands during trading, a decline of 98% from the average daily volume of 536,359 shares. The stock had previously closed at $1.97.

Several equities analysts have weighed in on VBIV shares. Zacks Investment Research downgraded shares of VBI Vaccines from a “hold” rating to a “sell” rating in a report on Friday, September 28th. ValuEngine raised shares of VBI Vaccines from a “hold” rating to a “buy” rating in a report on Thursday, November 1st. Finally, Oppenheimer started coverage on shares of VBI Vaccines in a report on Wednesday. They set an “outperform” rating and a $9.00 price target on the stock. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $10.50.

The company has a debt-to-equity ratio of 0.15, a current ratio of 1.61 and a quick ratio of 1.55.

VBI Vaccines (NASDAQ:VBIV) last released its earnings results on Friday, November 9th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.02). VBI Vaccines had a negative return on equity of 56.88% and a negative net margin of 6,345.29%. The company had revenue of $0.26 million during the quarter, compared to analysts’ expectations of $0.24 million. On average, analysts predict that VBI Vaccines Inc will post -0.94 earnings per share for the current fiscal year.

In other VBI Vaccines news, Director Tomer Kariv purchased 1,428,571 shares of the firm’s stock in a transaction that occurred on Monday, December 17th. The shares were bought at an average price of $1.40 per share, with a total value of $1,999,999.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Perceptive Advisors Llc purchased 14,285,714 shares of the firm’s stock in a transaction that occurred on Thursday, December 13th. The shares were acquired at an average cost of $1.40 per share, for a total transaction of $19,999,999.60. The disclosure for this purchase can be found here. 16.20% of the stock is currently owned by insiders.

Institutional investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC purchased a new stake in VBI Vaccines during the third quarter valued at $155,000. Dimensional Fund Advisors LP bought a new position in VBI Vaccines during the second quarter valued at $223,000. Paloma Partners Management Co bought a new position in VBI Vaccines during the second quarter valued at $254,000. Jane Street Group LLC bought a new position in VBI Vaccines during the second quarter valued at $331,000. Finally, Millennium Management LLC increased its position in VBI Vaccines by 118.7% during the second quarter. Millennium Management LLC now owns 531,117 shares of the biopharmaceutical company’s stock valued at $1,461,000 after acquiring an additional 288,214 shares during the last quarter. 32.45% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This piece was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another website, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2019/01/19/vbi-vaccines-vbiv-trading-up-2-5.html.

VBI Vaccines Company Profile (NASDAQ:VBIV)

VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the target virus.

Recommended Story: What does EPS mean?

Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply